Overview

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects. This is an open-label exploratory study with no change of therapeutic behavior but with standardized neuropsychologic follow-up.
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Collaborator:
Merck Serono S.A.S, France
Treatments:
Interferon beta-1a
Interferon-beta
Interferons